Morepen Labs executes business transfer with Medtech subsidiary

Morepen Laboratories announced the execution of a Business Transfer Agreement (BTA) with Morepen Medtech Limited, a subsidiary, on March 18, 2025. This move follows the approval of the company's members and involves the hiving-off of the Medical Devices Business on a "slump sale" basis as a going concern. Morepen Labs holds 80% of the equity share capital in Morepen Medtech. The transfer includes all rights, title, and interest in the undertaking, based on a valuation under Income Tax Rules. The final consideration will be subject to adjustments. Morepen Medtech Limited, incorporated as a subsidiary, has some entities belonging to the promoters' group/relatives as stakeholders. The transaction qualifies as a related party transaction conducted at arm's length.